A Randomized, Double‐Blind, Placebo‐Controlled Trial of Combined Nevirapine and Zidovudine Compared with Nevirapine Alone in the Prevention of Perinatal Transmission of HIV in Zimbabwe | Zendy

Paul Thistle | Zendy; Rachel F. Spitzer | Zendy; Richard H. Glazier | Zendy; Richard Pilon | Zendy; Gordon Arbess | Zendy; Andrew E. Simor | Zendy; Eleanor Boyle | Zendy; Inam Chitsike | Zendy; Tsungai Chipato | Zendy; Maureen Gottesman | Zendy; Michael Silverman | Zendy

Open Access

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Combined Nevirapine and Zidovudine Compared with Nevirapine Alone in the Prevention of Perinatal Transmission of HIV in Zimbabwe

Author(s) -

Paul Thistle,

Rachel F. Spitzer,

Richard H. Glazier,

Richard Pilon,

Gordon Arbess,

Andrew E. Simor,

Eleanor Boyle,

Inam Chitsike,

Tsungai Chipato,

Maureen Gottesman,

Michael Silverman

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/508869

Subject(s) - nevirapine , zidovudine , medicine , transmission (telecommunications) , placebo , human immunodeficiency virus (hiv) , randomized controlled trial , virology , pregnancy , pediatrics , viral disease , antiretroviral therapy , viral load , pathology , alternative medicine , electrical engineering , engineering , biology , genetics

A single dose of nevirapine (sdNVP) administered to both mother and infant can decrease mother-to-child transmission of human immunodeficiency virus (HIV) by 47%, compared with ultra-short course zidovudine therapy (usZDV). There is limited data about the benefit of usZDV added to sdNVP to prevent mother-to-child transmission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research